文献速递白血病

老年新诊断初发急性早幼粒细胞白血病患者接受全反式维甲酸联合蒽环类方案治疗的长期结局

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
PubMed 文献 · Leukemia · 2017-06-06

该研究纳入1996至2012年PETHEMA登记中389例≥60岁新诊断初发急性早幼粒细胞白血病患者,268例(69%)符合条件,比较LPA2005试验与既往非年龄适配方案LPA96&LPA99的长期结局。LPA2005组与LPA96&99组的5年无病生存率分别为87%与69%(P=0.04),5年总生存率分别为74%与60%(P=0.06),5年非复发死亡率分别为5%与18%(P=0.15),5年累积复发率分别为7%与12%(P=0.23)。

要点

  • LPA2005组5年无病生存率87%,高于LPA96&99组的69%(P=0.04)。
  • LPA2005组5年总生存率74%,LPA96&99组为60%(P=0.06)。
  • LPA2005组5年非复发死亡率5%,LPA96&99组为18%(P=0.15)。

核心结论

  • 采用全反式维甲酸联合蒽环类单药化疗的较低强度一线方案,可使老年急性早幼粒细胞白血病患者获得改善的结局。

研究设计与样本

  • 研究纳入1996至2012年PETHEMA登记中年龄≥60岁的新诊断初发急性早幼粒细胞白血病患者,共389例,其中268例(69%)符合条件。
  • 不符合条件的原因包括继发性急性早幼粒细胞白血病(19%)和不适合化疗(11%)。
  • 中位年龄67岁,LPA2005队列与LPA96&LPA99队列之间无相关差异。
  • 比较LPA2005试验与既往采用非年龄适配方案的PETHEMA试验(LPA96&LPA99)的长期结局。

主要发现

  • 共216例患者(81%)达到完全缓解,各试验之间无差异。
  • LPA2005组与LPA96&99组的5年非复发死亡率分别为5%与18%(P=0.15)。
  • LPA2005组与LPA96&99组的5年累积复发率分别为7%与12%(P=0.23)。
  • LPA2005组与LPA96&99组的5年无病生存率分别为87%与69%(P=0.04)。
  • LPA2005组与LPA96&99组的5年总生存率分别为74%与60%(P=0.06)。

关键数值与推荐

  • LPA2005组5年非复发死亡率5% vs LPA96&99组18%(P=0.15)。
  • LPA2005组5年累积复发率7% vs LPA96&99组12%(P=0.23)。
  • LPA2005组5年无病生存率87% vs LPA96&99组69%(P=0.04)。
  • LPA2005组5年总生存率74% vs LPA96&99组60%(P=0.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment outcome in older patients with acute promyelocytic leukemia (APL) is lower compared with younger patients, mainly because of a higher induction death rate and postremission non-relapse mortality (NRM). This prompted us to design a risk- and age-adapted protocol (Programa Español de Tratamientos en Hematología (PETHEMA)/HOVON LPA2005), with dose reduction of consolidation chemotherapy. Patients aged ⩾60 years reported to the PETHEMA registry and were treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimens according to three consecutive PETHEMA trials that were included. We compared the long-term outcomes of the LPA2005 trial with the preceding PETHEMA trials using non-age-adapted schedules (LPA96&LPA99). From 1996 to 2012, 389 older patients were registered, of whom 268 patients (69%) were eligible. Causes of ineligibility were secondary APL (19%), and unfit for chemotherapy (11%). Median age was 67 years, without relevant differences between LPA2005 and LPA96&LPA99 cohorts. Overall, 216 patients (81%) achieved complete remission with no differences between trials. The 5-year NRM, cumulative incidence of relapse, disease-free survival and overall survival in the LPA2005 vs the LPA96&99 were 5 vs 18% (P=0.15), 7 vs 12% (P=0.23), 87 vs 69% (P=0.04) and 74 vs 60% (P=0.06). A less intensive front-line regimen with ATRA and anthracycline monochemotherapy resulted in improved outcomes in older APL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Martínez-Cuadrón D, Montesinos P, Vellenga E, et al. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia. 2017. PMID: 28584252. doi:10.1038/leu.2017.178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。